T cell vaccination: clinical application in autoimmune diseases

Area of Science:

• Neuroimmunology
• Autoimmunity
• Clinical Immunology

Background:

• T cell responses to myelin basic protein (MBP) are central to multiple sclerosis (MS) pathogenesis.
• Autoreactive T cells accumulate in the brain lesions of MS patients, driving inflammation.
• Targeting these MBP-autoreactive T cells offers a potential therapeutic strategy for MS.

Purpose of the Study:

• To review the application of T cell vaccination in MS patients.
• To evaluate the efficacy of T cell vaccination in depleting MBP-reactive T cells.
• To assess the clinical and radiological outcomes in MS patients treated with T cell vaccination.

Main Methods:

• Phase I clinical trial of T cell vaccination using inactivated MBP autoreactive T cells.
• Longitudinal clinical evaluation and magnetic resonance imaging (MRI) for disease monitoring.
• Assessment of immune response, including regulatory T cell induction and clonotype specificity.

Main Results:

• T cell vaccination induced a specific regulatory T cell network.
• Circulating MBP-reactive T cells were depleted in a clonotype-specific and long-lasting manner.
• Vaccinated MS patients showed a trend towards reduced clinical exacerbations, disability, and MRI-detected brain lesions compared to controls.

Conclusions:

• T cell vaccination is a promising immunotherapy for MS, inducing specific and durable immune regulation.
• The findings support further investigation into T cell vaccination's efficacy and broader application in autoimmune diseases.
• Clonotype-specific depletion of autoreactive T cells represents a novel therapeutic approach for autoimmune conditions.